OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
LOS ANGELES, April 29, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq:SCYX) concerning possible violations of federal securities laws. Investors who purchased SCYNEXIS securities: (1) pursuant or traceable to the Company’s initial public offering on or about May 2, 2014; and/or (2) from May 2, 2014 through March 2, 2017, inclusive (the “Class Period”) should contact the firm prior to the May 8, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The Complaint alleges that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company’s lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug’s approval prospects and/or commercial viability; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On March 2, 2017, SCYNEXIS announced that the U.S. Food & Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation. Upon release of this information, the stock price of SCYNEXIS dropped materially, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
